OpenLB
Open Library of Bioscience
Advanced Search
Oncology letters
Jan, 2025;29 (1): 37.

Role of four and a half LIM domain protein 1 in tumors (Review).

Yun Tao, Yaxun Wu, Rong Shen, Song He, Xiaobing Miao
Author Information
  1. Yun Tao: Department of Pathology, Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu 226361, P.R. China.
  2. Yaxun Wu: Department of Pathology, Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu 226361, P.R. China.
  3. Rong Shen: Department of Pathology, Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu 226361, P.R. China.
  4. Song He: Department of Pathology, Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu 226361, P.R. China.
  5. Xiaobing Miao: Department of Pathology, Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu 226361, P.R. China.
PMID: 39512507 DOI: 10.3892/ol.2024.14783

Abstract

As a cytoskeletal protein, the four and a half LIM domain protein 1 (FHL1) is widely expressed in various cells, particularly skeletal and cardiac muscle cells. FHL1 is involved in the development of the skeletal muscle and myocardium, regulations of gene transcription and thyroid function, and other physiological processes. Its expression is closely related to numerous diseases, such as skeletal muscle disease and viral infections. With the advances in research, the role of FHL1 in the development of tumors is also being revealed. The mechanism of FHL1 in the regulation of tumor growth is complex and is becoming a research focus. It is also expected to become a potential target for tumor therapy. Therefore, the present article reviewed the progress in research on the role of FHL1 in cancer.

Keywords

FHL1 cell proliferation cytoskeletal protein drug resistance tumor

References

  1. Endocrine. 2024 Jul;85(1):238-249 [PMID: 38191984]
  2. BMC Cancer. 2018 Feb 17;18(1):193 [PMID: 29454310]
  3. Clin Proteomics. 2022 Nov 21;19(1):44 [PMID: 36404333]
  4. J Cancer. 2021 Jul 3;12(17):5345-5354 [PMID: 34335951]
  5. Diagnostics (Basel). 2022 May 03;12(5): [PMID: 35626289]
  6. Gene. 1998 Aug 17;216(1):163-70 [PMID: 9714789]
  7. Exp Cell Res. 2022 Jun 1;415(1):113107 [PMID: 35306026]
  8. J Cell Mol Med. 2011 Jan;15(1):72-85 [PMID: 19840196]
  9. Comb Chem High Throughput Screen. 2023;26(12):2226-2237 [PMID: 36752296]
  10. Int J Cardiol. 2016 Jul 1;214:136 [PMID: 27061647]
  11. J Cell Biol. 2018 Apr 2;217(4):1335-1351 [PMID: 29434030]
  12. Biochem Cell Biol. 2022 Aug 1;100(4):301-308 [PMID: 35916339]
  13. Aging (Albany NY). 2021 Jun 1;13(11):15269-15284 [PMID: 34074803]
  14. Blood. 2003 Apr 15;101(8):3294-301 [PMID: 12515724]
  15. FEBS Lett. 2010 Nov 19;584(22):4511-6 [PMID: 20969868]
  16. Oncogene. 2013 Apr 25;32(17):2140-9 [PMID: 22689052]
  17. J Breast Cancer. 2020 Aug 25;23(4):355-372 [PMID: 32908787]
  18. Leuk Lymphoma. 2022 Aug;63(8):1897-1906 [PMID: 35249471]
  19. Biochem Biophys Res Commun. 2021 Jan 22;537:125-131 [PMID: 33401146]
  20. Oncotarget. 2016 Mar 22;7(12):14537-50 [PMID: 26908444]
  21. J Cell Physiol. 2020 May;235(5):4667-4678 [PMID: 31637727]
  22. Comput Math Methods Med. 2022 Aug 16;2022:7891222 [PMID: 36017148]
  23. Cell Signal. 2024 Jul;119:111155 [PMID: 38565413]
  24. Dis Markers. 2022 Aug 19;2022:1354005 [PMID: 36033826]
  25. Int J Biochem Cell Biol. 2012 Feb;44(2):320-6 [PMID: 22094188]
  26. Neuromuscul Disord. 2021 Sep;31(9):847-853 [PMID: 34366191]
  27. Gene. 2022 Feb 15;811:146086 [PMID: 34856364]
  28. Neurology. 2011 Nov 29;77(22):1951-9 [PMID: 22094483]
  29. Muscle Nerve. 2013 Jan;47(1):127-34 [PMID: 23169582]
  30. J Cancer. 2019 Oct 19;10(25):6414-6421 [PMID: 31772674]
  31. Cancer Biol Med. 2020 May 15;17(2):270-281 [PMID: 32587768]
  32. Neuromuscul Disord. 2018 Jun;28(6):521-531 [PMID: 29735270]
  33. Cancer Sci. 2008 Jul;99(7):1326-33 [PMID: 18422756]
  34. J Cell Sci. 2014 May 15;127(Pt 10):2269-81 [PMID: 24634512]
  35. Ann Vasc Surg. 2011 Feb;25(2):240-7 [PMID: 21126853]
  36. Eur J Med Res. 2024 Jun 4;29(1):309 [PMID: 38831471]
  37. J Clin Invest. 2015 Dec;125(12):4612-24 [PMID: 26551678]
  38. Int J Biochem Cell Biol. 2009 Jul;41(7):1613-8 [PMID: 19401155]
  39. ESMO Open. 2016 Feb 17;1(1):e000009 [PMID: 27843583]
  40. Cell Oncol (Dordr). 2023 Aug;46(4):1001-1014 [PMID: 36929488]
  41. Front Genet. 2018 Jul 23;9:273 [PMID: 30083183]
  42. Int J Clin Exp Med. 2015 Nov 15;8(11):20965-70 [PMID: 26885026]
  43. Cell J. 2022 May;24(5):239-244 [PMID: 35717564]
  44. Nature. 2019 Oct;574(7777):259-263 [PMID: 31554973]
  45. Stem Cell Res. 2024 Mar;75:103307 [PMID: 38244535]
  46. Biochem Biophys Res Commun. 2011 Feb 11;405(2):216-21 [PMID: 21219870]
  47. J Clin Invest. 2009 Feb;119(2):349-61 [PMID: 19139564]
  48. Nat Commun. 2017 Jan 17;8:14059 [PMID: 28094252]
  49. Gene. 2014 Jun 1;542(2):182-9 [PMID: 24657059]
  50. Small GTPases. 2019 Sep;10(5):361-366 [PMID: 28489964]
  51. Mol Med Rep. 2013 Feb;7(2):649-53 [PMID: 23184087]
  52. Front Neurol. 2020 Sep 15;11:1014 [PMID: 33041974]
  53. Chin J Physiol. 2023 Nov-Dec;66(6):534-545 [PMID: 38149566]
  54. IUBMB Life. 2012 Nov;64(11):921-30 [PMID: 23086815]
  55. PLoS One. 2014 Oct 01;9(10):e108708 [PMID: 25272045]
  56. EBioMedicine. 2020 Feb;52:102664 [PMID: 32062360]
  57. Int J Mol Med. 2010 Aug;26(2):241-7 [PMID: 20596604]
  58. J Cancer. 2020 Aug 25;11(20):6122-6132 [PMID: 32922552]
  59. Immunotherapy. 2023 Mar;15(4):235-252 [PMID: 36695131]
  60. J Cell Mol Med. 2010 Dec;14(12):2702-20 [PMID: 20874719]
  61. J Hum Genet. 2019 Sep;64(9):919-926 [PMID: 31273321]
  62. FEBS Lett. 2021 Jan;595(1):85-98 [PMID: 33053208]
  63. Sci Rep. 2022 Oct 6;12(1):16693 [PMID: 36202977]
  64. Ann Surg Oncol. 2008 Aug;15(8):2293-300 [PMID: 18465173]
  65. BMC Cancer. 2014 Jun 22;14:463 [PMID: 24952875]
  66. C R Biol. 2021 Apr 21;343(4):79-89 [PMID: 33988325]
  67. Biochem Biophys Res Commun. 2020 Feb 26;523(1):105-111 [PMID: 31836140]
  68. Pathol Int. 2024 Sep;74(9):520-529 [PMID: 39119938]
  69. Int J Cancer. 2012 Jun 1;130(11):2549-56 [PMID: 21702045]
  70. Cell Biol Toxicol. 2023 Oct;39(5):2069-2087 [PMID: 35142956]
  71. Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338231222389 [PMID: 38226611]
  72. Nat Commun. 2023 Oct 26;14(1):6605 [PMID: 37884534]
  73. Int J Oncol. 2013 Jan;42(1):141-50 [PMID: 23123766]
  74. Cell. 2004 Dec 29;119(7):969-79 [PMID: 15620355]
  75. J Hum Genet. 2023 Jul;68(7):477-484 [PMID: 36864287]
  76. Oncol Lett. 2020 Jun;19(6):3781-3788 [PMID: 32382330]
  77. J Nat Prod. 2024 Apr 26;87(4):837-848 [PMID: 38417401]
  78. JACC Case Rep. 2020 Feb 26;2(3):372-377 [PMID: 34317245]
  79. Funct Integr Genomics. 2024 Feb 7;24(1):25 [PMID: 38324167]
  80. Rev Esp Cardiol (Engl Ed). 2022 Nov;75(11):968-970 [PMID: 35577730]
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0FHL1proteinskeletalmuscleresearchtumorcytoskeletalfourhalfLIMdomain1cellsdevelopmentroletumorsalsowidelyexpressedvariousparticularlycardiacinvolvedmyocardiumregulationsgenetranscriptionthyroidfunctionphysiologicalprocessesexpressioncloselyrelatednumerousdiseasesdiseaseviralinfectionsadvancesrevealedmechanismregulationgrowthcomplexbecomingfocusexpectedbecomepotentialtargettherapyThereforepresentarticlereviewedprogresscancerRoleReviewcellproliferationdrugresistance

Similar Articles

Cited By